(Lung Cancer) Is Trastuzumab + Pertuzumab + Docetaxel Effective?
(Lung Cancer) Is Trastuzumab + Pertuzumab + Docetaxel Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Is Trastuzumab + Pertuzumab + Docetaxel Effective?
- February 9, 2022
- 1 min read
On January 24, 2022, Julien Mazieres et al. from Universite Paul Sabatier published in the medical journal Journal of Clinical Oncology the efficacy and safety results of Trastuzumab + Pertuzumab + Docetaxel for previously treated HER2-positive non-small cell lung cancer patients in the IFCT-1703 R2D2 Phase II clinical trial.
The IFCT-1703 R2D2 Phase II clinical trial was a multi-center randomized trial conducted in three-week treatment cycles, administering Trastuzumab 6 mg/kg (initial dose 8 mg/kg) + Pertuzumab 420 mg (initial dose 840 mg) + Docetaxel 75 mg/m2 to HER2-positive non-small cell lung cancer patients with prior platinum-based therapy (N=45). The primary endpoint was objective response rate, with secondary endpoints including duration of treatment, progression-free survival, and safety.
Patient characteristics included a median age of 64.5 years (31-84), 35% smokers, 72% female, 15% with performance status score of 2, and 30% with brain metastases. The study results were as follows:
The primary endpoint objective response rate was 29% (N=13), with a disease stabilization rate of 58% (N=26). The secondary endpoint median progression-free survival was 6.8 months, and the median duration of response was 11 months.
Regarding safety, the grade 3-4 adverse event rate was 64%, with a treatment discontinuation rate due to adverse events of 0%. The most common adverse events were neutropenia 33%, diarrhea 13%, and anemia 9%.
Based on the IFCT-1703 R2D2 trial results, Julien Mazieres et al. stated that Trastuzumab + Pertuzumab + Docetaxel for previously treated HER2-positive non-small cell lung cancer patients demonstrated good anti-tumor efficacy with acceptable tolerability, and this regimen should be considered as a treatment option for these patients in the future.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.01455
-
Investigational Drugs
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.